Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

llion (2006: US$nil) of which US$205.0 million (2006: US$nil) relates to capitalised in-process R&D ("IPR&D") for DYNEPO (primarily the oncology indication), as the Group considers it unlikely that it will pursue the indication for commercialisation. See Note 7 for further details.

Excluding these intangible impairment charges of US$256.4 million and the US$100.0 million charge on the effective settlement of the pre-existing relationship with New River, R&D expenditure in the year to December 31, 2007 was US$418.8 million or 19% of product sales (2006: US$295.8 million) an increase of US$123.0 million.

The increase in R&D expenditure in 2007 was due to Phase 3(b) and Phase 4 studies to support new product launches; the continuation of Phase 3 trials on velaglucerase alfa (GA-GCB); the development of the Women's Health franchise and JUVISTA; the pre-clinical development of three HGT projects and the newly in-licensed products from Amicus Therapeutics, Inc. ("Amicus") and Alba Therapeutics Corporation ("Alba").

For the year to December 31, 2007 R&D included a charge of US$16.6 million (2006: US$3.9 million) for share based compensation which included a US$4.6 million (2006: US$nil) cumulative catch up charge in respect of 2005 option awards, for further information see SG&A below.

Selling, general and administrative (SG&A) expenses

SG&A expenses increased from US$1,219.9 million (79% of product sales) in the year to December 31, 2006 to US$1,381.1 million in 2007 (64% of product sales), an increase of 13%, which is less than the product sales increase of 41%.

Year to December 31, 2007 2006 Change

US$M US$M %

_______ _______ _______

Sales costs 310.7 233.2 +33

Marketing costs 401
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... OncLive® is pleased to announce that ... Strategic Alliance Partnership program. , By participating ... will have the opportunity to work with the ... research initiatives, community-directed cancer prevention programs, and other ... OncLive to educate their peers by providing insights ...
(Date:7/22/2014)... 21, 2014 (PRWEB) July 23, 2014 ... Rutgers University. , The goal of the ... the full spectrum of scientists working in the ... development topics that represent the most promising directions ... to:,     Provide faculty and government ...
(Date:7/22/2014)... of rod-shaped metal nanoparticles in water with ultrasound and ... bits. Why? No one yet knows exactly. But researchers ... have clocked their speedand it,s fast. At up to ... faster than any nanoscale object submerged in liquid ever ... opened up the possibility that they could be used ...
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer ... cosmetics, and other markets, announced today that it has ... qualified private investors led by Novit L.P., an investment ... transaction involved the signing of a Securities Purchase Agreement ... Stock at a price per share of $1.00, resulting ...
Breaking Biology Technology:OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3
... Sinobiopharma Pharmaceutical Group (OTC Bulletin Board: SNBP) is ... Tan as Director of Marketing.Ms. Tan joins Sinobiopharma ... as a China-based Unit Marketing Director for Organon, ... Organon, Ms. Tan held senior marketing management roles ...
... 8 Biopharmaceutical company Kiadis,Pharma reported preliminary ... mismatched bone marrow transplantations. Data was presented ... Roy during the prestigious,Presidential Symposium at the ... Goteborg, Sweden, on Monday, March 30, 2009. ...
... Inc. announced today that it has entered into ... NYSE: SNY ), providing the global ... platform for the research, development and commercialization of ... (ADCC). "We are extremely pleased about our partnership ...
Cached Biology Technology:Sinobiopharma, Inc. Appoints New Director of Marketing 2Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations 2BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis 2
(Date:7/23/2014)... local and national governments struggle to deal with ever-growing ... refining the picture of just how much there is ... ACS journal Environmental Science & Technology , their ... developed countries discard floods into just seven developing countries ... who live there. , Knut Breivik and colleagues note ...
(Date:7/23/2014)... the International Journal of Fuzzy Systems ( ... Systems Association (TFSA). The cooperation will allow the journal ... fuzzy research., The International Journal of Fuzzy Systems ... with the theory, design and application of fuzzy systems, ... ranging from hardware to software. Launched in 1999, the ...
(Date:7/23/2014)... is available in German . ... modalities for orientation, some of which might be very ... the polarization pattern produced by sunlight in the atmosphere ... Max Planck Institute for Ornithology in Seewiesen, Germany, and ... that a night active mammal, the greater mouse-eared bat, ...
Breaking Biology News(10 mins):Bats use the evening sky's polarization pattern for orientation 2
... Sobrado, assistant professor of biochemistry at Virginia Tech, ... Prize, administered by the Ministry of Science and ... research is "a significant contribution to the diagnosis ... to a release distributed my MICIT. Sobrado, ...
... may have just provided the medical community a new way ... blocks of life forms and functions. University of Central ... program to analyze RNA motifs the subunits that make ... three building blocks of life along with DNA and proteins. ...
... in mice suggests a novel strategy for treating damaged ... approach potentially could improve cardiac function, minimize scar size, ... and avoid the risk of tissue rejection. In ... ONE , ( http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0030329 ) the researchers isolated and ...
Cached Biology News:Contributions to diagnosis, treatment of tropical diseases recognized 2Stem cell study in mice offers hope for treating heart attack patients 2Stem cell study in mice offers hope for treating heart attack patients 3
... a platform for fully automated systems for ... easily be configured for applications ranging from ... allows closed loop screening, which means it ... generating, cherry picking and follow up studies ...
... devices for the fast and reliable clarification/filtration of ... 500 l. They can be used in fixed ... Features: High-flux Polyethersulphonemembrane 0.8 ... volume ( Fast and reproducible performance ...
... Prelude Workstation fully automates pharmaceutical sample ... extraction, sample transfer, mixing and dilutions. ... UV detection. The Prelude performs these ... CFR Part 11. The Prelude ...
... in any standard fixed-angle microcentrifuge rotor ... g.,Spin- centrifuge tube filters consist of ... centrifuge tube. They filter by centrifugation ... sample preparation, removal of cells from ...
Biology Products: